ARTA
SYRE icon

A.R.T. Advisors’s Spyre Therapeutics SYRE Stock Holding History

A.R.T. Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-405
Closed -$78K – 1701
2019
Q3 		$78K Sell
405
-428
-51% -$83.4K ﹤0.01% 1283
2019
Q2 		$143K Buy
+833
New +$144K 0.01% 1152
2018
Q2 		– Sell
-739
Closed -$183K – 1736
2018
Q1 		$183K Buy
+739
New +$134K 0.01% 1285

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

A.R.T. Advisors's SYRE Position: Q4 2019 in Review

A.R.T. Advisors sold out of Spyre Therapeutics (SYRE) in Q4 2019, closing a stake of 405 shares — an estimated $78K sold.

A.R.T. Advisors first reported a position in SYRE in Q1 2018 and held it in 3 quarters. The position peaked at $183K in Q1 2018. 68 funds tracked by Wall St. Rank hold SYRE as of Q4 2019.

  • A.R.T. Advisors reported no remaining Spyre Therapeutics position as of Q4 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 405 Spyre Therapeutics shares in Q4 2019, an estimated $78K.
  • A.R.T. Advisors first reported a position in Spyre Therapeutics in Q1 2018 and held it in 3 quarters.
  • A.R.T. Advisors's Spyre Therapeutics position peaked at $183K in Q1 2018.
  • 68 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.